drugset / Trial / NCT01292421

Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination

NCT01292421

RandomizedParallel-groupDouble-blindPrevention

Summary

RATIONALE: Hepatitis B antigen peptide (HBsAg) vaccine may help the body build an immune response and help prevent hepatitis B. PURPOSE: This clinical trial studies edible HBsAg vaccine therapy in healthy participants who have undergone previous vaccination.

Timeline

Start
2013-02
Primary completion
2013-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B vaccine Vaccine Oral

Indications

No indication recorded.